A Biomedical Hub

A Rapid Evolution

Hong Kong's biotechnology industry is rapidly evolving to take advantage of new technologies and markets, attracting a wide range of foreign companies, from giants like Eli Lilly to new start-ups. Drawing on expertise in both Western and Traditional Chinese Medicine (TCM), biotech companies based in Hong Kong are assured of a large pool of talent and capital to develop the Asian markets.

A Pharmaceuticals Centre

Hong Kong has a sophisticated healthcare system, presenting a strong local market for leading pharmaceutical companies. Excited by the possibilities for growth, many traditional blue chip companies in Hong Kong have recently established biotechnology investment arms.

The rigorous intellectual property protection legislation in Hong Kong enhances the development of new technology and innovation.

Leveraging the Mainland

Hong Kong's proximity to the Mainland, one of the fastest growing pharmaceutical markets in the world, makes it an ideal operations base for international biotechnology companies seeking to exploit the business potentials in Asia. The potential for commercialisation of its traditional medicines and herbal drugs remains largely unexplored.

With a population of over 1.3 billion, in 56 ethnic groups, the Mainland endows with a highly diversified human genome pool. Hong Kong based companies can tap the vast resources and participate in joint applied genomic and biotech research projects to develop new biotechnology applications at low cost.

A Research Resource

The rigorous intellectual property protection legislation in Hong Kong enhances the development of new technology and innovation. This is recognised by both international and mainland Chinese firms. Hong Kong has world-class standards and international recognition in the area of clinical research, conducted mainly at its two teaching hospitals. The local universities also enjoy state-of-the-art research facilities and close cooperation with the public hospital network and private sector.